Search

Your search keyword '"Baudin, Eric"' showing total 1,202 results

Search Constraints

Start Over You searched for: Author "Baudin, Eric" Remove constraint Author: "Baudin, Eric"
1,202 results on '"Baudin, Eric"'

Search Results

3. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial

4. Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers

5. French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines/Association Francophone de Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1

6. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study

7. Recommandations du réseau national ENDOCAN-COMETE pour la prise en charge des phéochromocytomes et paragangliomes métastatiques

8. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

11. Recommandations conjointes du réseau National ENDOCAN-COMETE, de l’Association francophone de chirurgie endocrinienne et de la Société française d’urologie pour la prise en charge du carcinome corticosurrénalien

15. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study

16. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial

21. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network

22. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

23. Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era

24. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

26. Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network.

27. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)

28. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma

31. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study

33. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study

34. EPAS1‐mutated paragangliomas associated with haemoglobin disorders

35. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer

36. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily

38. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

39. The Immune Landscape of Cancer

40. Comprehensive Characterization of Cancer Driver Genes and Mutations

41. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

42. Pathogenic Germline Variants in 10,389 Adult Cancers

43. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

44. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples

45. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

46. Oncogenic Signaling Pathways in The Cancer Genome Atlas

47. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

48. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

49. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

50. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

Catalog

Books, media, physical & digital resources